Method for treating blood plasma employing a hollow fiber membrane

• US 4,402,940 A
• Filed: 09/17/1982
• Issued: 09/06/1983
• Est. Priority Date: 03/12/1982
• Status: Expired due to Term

• Current Assignee: Kuraray Company Limited
• Original Assignee: Kuraray Company Limited
• Inventors: Smith, James, Nose, Yukihiko, Malchesky, Paul S., Sueoka, Akinori, Shinagawa, Shigeru, Asanuma, Yoshihiro, Werynski, Andrej, Kayashima, Koji
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US06/418,551
• Time in Patent Office: 354 Days
• Field of Search: 424/101
• US Class Current: 424/530
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3482 by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
• CPC Class Codes: B01D 69/02 characterised by their properties
• CPC Class Codes: B01D 69/08 Hollow fibre membranes manufacture of hollow fibres D01D5/24, D01F1/08

Abstract

This invention provides a method for treating blood plasma wherein a hollow fiber membrane which comprises at least a skin layer on one surface of the membrane and also a porous layer inside the membrane is employed. The skin layer of the membrane has micropores with average pore size of 50 to 450 A, and the membrane shows a water permeability of 80 ml/m².hr.mmHg or more, and permeabilites for human blood plasma albumin of 85% or more and for human blood plasma immunoglobulin G(IgG) of 80% or more, and a rate of inhibition against human blood plasma immunoglobulin M(IgM) of 40% or more. Use of the above mentioned hollow fiber membrane, which makes it possible to selectively remove immune complex, rheumatoid factors, etc., without decrease in levels of immunological functions, brings excellent effects on therapy of autoimmune diseases.

Claims

1. A method for treating the blood plasma to selectively reduce the amount of a disease factor therein comprising fractionating the plasma with a hollow fiber membrane comprising a skin layer on at least one surface of said membrane and a porous layer inside said membrane with average pore size of micropores of said skin layer in the range of 50 to 450 A, that of micropores of the porous layer ranging from 500 to 15,000 A, void volume of said membrane at a level of 50 to 85% and water permeability at a level of 80 ml/m².hr.mmHg or higher, such that the amount of the disease factor in one of the fractions produced is decreased.

2. A method for treating the blood plasma as claimed in claim 1, wherein said hollow fiber membrane has a skin layer on its exterior surface and a porous supporting layer both inside and on the interior surface of said membrane.

3. A method for treating the blood plasma as claimed in claim 1 or claim 2, wherein said hollow fiber membrane shows permeabilities for human blood plasma albumin and human blood plasma immunoglobulin G of 85% or more and 80% or more, respectively, and a rate of inhibition against human blood plasma immunoglobulin M of 40% or more.

4. A method for treating the blood plasma as claimed in any one of claims 1 to 3, wherein the skin layer of said hollow fiber membrane is 100 to 30,000 A thick.

5. A method for treating the blood plasma as claimed in any one of claims 1 to 4, wherein thickness of the hollow fiber membrane ranges 10 to 90μ

and inside diameter thereof is in the range of 50 to 800μ

.

6. A method for treating the blood plasma as claimed in any one of claims 1 to 5, wherein water permeability is in the range of 80 to 1,500 ml/m².hr.mmHg.

7. A method for treating the blood plasma as claimed in any one of claims 1 to 6, wherein the hollow fiber membrane is composed of a vinyl alcohol polymer.

8. A method for treating the blood plasma as claimed in claim 7, wherein said vinyl alcohol polymer is an ethylene-vinyl alcohol copolymer.